Literature DB >> 7712736

Patient-reported symptoms associated with graft reactions in high-risk patients in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group.

M T Kamp1, N E Fink, C Enger, M G Maguire, W J Stark, R D Stulting.   

Abstract

The Collaborative Corneal Transplantation Studies (CCTS) were designed to evaluate the effect of donor-recipient histocompatibility matching and cross-matching on the survival of corneal transplants in high-risk patients. We now report on the role of symptoms in the detection of corneal allograft reactions in the CCTS and on the relationship between symptom reporting and graft survival. The 456 patients transplanted in the CCTS were followed for a minimum of 2 years or until graft failure. The follow-up protocol included 11 scheduled examinations in the first year, four examinations during the second year, and examinations every 6 months thereafter. Interim examinations were performed in response to patient-reported symptoms. At every examination, patients were asked specifically if they had redness, sensitivity to light, loss of vision, or pain (RSVP). Of the 456 patients transplanted, 62% had at least one graft reaction. Patients diagnosed with reactions at scheduled visits in the first postoperative year were 2.5 times more likely to report symptoms than those without reactions. Reports of red eye and vision loss were strongly associated with allograft reaction. However, these symptoms were neither highly sensitive nor specific for reaction (sensitivity = 46%, specificity = 70% at 6 months). The severity of reaction influenced the reporting of symptoms: 69% of patients with severe reactions reported symptoms versus 48% of patients with mild reactions (p < 0.001). The only patient characteristic associated with reliable symptom reporting was age, with younger patients with reactions being more likely to report symptoms.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7712736

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  8 in total

Review 1.  Immunology of corneal transplantation.

Authors:  W H Constad; K Taraschanskiy
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

Review 2.  Graft failure: I. Endothelial cell loss.

Authors:  Ilse Claerhout; Hilde Beele; Philippe Kestelyn
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

3.  E-Selectin Mediates Immune Cell Trafficking in Corneal Transplantation.

Authors:  Thomas H Dohlman; Antonio Di Zazzo; Masahiro Omoto; Jing Hua; Julia Ding; Pedram Hamrah; Sunil K Chauhan; Reza Dana
Journal:  Transplantation       Date:  2016-04       Impact factor: 4.939

4.  Regulatory T cells promote corneal endothelial cell survival following transplantation via interleukin-10.

Authors:  Giulia Coco; William Foulsham; Takeshi Nakao; Jia Yin; Afsaneh Amouzegar; Yukako Taketani; Sunil K Chauhan; Reza Dana
Journal:  Am J Transplant       Date:  2019-10-30       Impact factor: 8.086

Review 5.  Systemic Immunomodulatory Strategies in High-risk Corneal Transplantation.

Authors:  Tulio B Abud; Antonio Di Zazzo; Ahmad Kheirkhah; Reza Dana
Journal:  J Ophthalmic Vis Res       Date:  2017 Jan-Mar

6.  The purinergic receptor antagonist oxidized adenosine triphosphate suppresses immune-mediated corneal allograft rejection.

Authors:  William Foulsham; Sharad K Mittal; Takeshi Nakao; Giulia Coco; Yukako Taketani; Sunil K Chauhan; Reza Dana
Journal:  Sci Rep       Date:  2019-06-13       Impact factor: 4.379

7.  Application of benzonase in preparation of decellularized lamellar porcine corneal stroma for lamellar keratoplasty.

Authors:  Jing Liu; Zhihan Li; Jie Li; Zuguo Liu
Journal:  J Biomed Mater Res A       Date:  2019-08-06       Impact factor: 4.396

Review 8.  Immunology and Donor-Specific Antibodies in Corneal Transplantation.

Authors:  Joanna Major; Bartosz Foroncewicz; Jacek Paweł Szaflik; Krzysztof Mucha
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-11-06       Impact factor: 4.291

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.